The HRB-supported UCC Cancer Trials Group is among six successful UCC projects that have received additional funding from the HRB for communication and dissemination activities, bringing scientific discoveries closer to the public. The HRB KTA programme supports researchers to work together to shape and deliver knowledge translation activities that will improve the exchange of research findings and its translation into policy and practice.Read more
Professor Roisin Connolly awarded a HRB Knowledge Translation Award for UCC Cancer Trials Group's Art4Knowledge Art Therapy Project22 Nov 2022
15 Nov 2022
The first annual UCC Cancer Trials Group (UCC CTG) Retreat will take place on 25th November, with patients and public invited to join the afternoon lunch session.Read more
New cancer research will help individualise treatment for patients with early-stage breast cancer to improve survival14 Sep 2022
New research at Cancer Research @UCC, funded by Breakthrough Cancer Research, aims to advance the personalisation of treatment for patients with early-stage breast cancer.
“Our goal is to help improve treatment decision-making for an individual patient with breast cancer, meaning that certain patients could avoid receiving toxic and futile therapies, while other patients could be directed towards a more intensive approach in order to maximise their cancer outcome and improve survival rates.” Dr Maeve Hennessy, Breakthrough Clinical Cancer Research FellowRead more
16 Jun 2022
A new €300,000 Irish Cancer Society research project based at Cork University Hospital (CUH) and supported by the UCC Cancer Trials Group will trial new methods to help make crucial improvements to quality of life for men facing devastating cancer diagnoses.Read more
Precision Oncology Ireland: Irish university, cancer charity and industry sectors join forces to improve cancer patient outcomes05 Jan 2021
For the first time ever, Ireland’s six main cancer charities have come together with government and industry to help fund a joint university precision medicine programme. Professor Mark Tangney, Principal Investigator in Cancer Research @UCC, explains why.